Market research
HJLI Hancock Jaffe Laboratories Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 98M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- 0.0%
- Beta
- 1.54
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 98M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- 0.0%
- Beta
- 1.54
About
About Hancock Jaffe Laboratories Inc
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Research context
Hancock Jaffe Laboratories Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HJLI discussion.
5 years, 7 months ago
Hancock Jaffe Laboratories, Inc is currently in a long term downtrend where the price is trading 6.1% below its 200 day moving average.
From a valuation standpoint, the stock is 83.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 216.9.
Hancock Jaffe Laboratories, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 90.9% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 61.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Hancock Jaffe Laboratories, Inc gets an overall score of 1/5.